Development of the new synthetic triterpenoid cddo-2P-IM for chemoprevention of the ards of covid-19
Ended Project Grant Awarded Last action
- Award ID
- R43CA243842
- Recipient
-
Triterpenoid Therapeutics Inc. UEI JA25GYTMYJP3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $530,281
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- New Hampshire, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$19,513 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $249,799 | |
| Original award | $299,995 |
Show all 15
Quick answers
Who received award R43CA243842?
R43CA243842 was awarded to Triterpenoid Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2020.
How much is award R43CA243842 worth?
$530,281 has been obligated on R43CA243842.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award